Welcome to the MSS2024!

Thursday, 24.10.2024 • 19:00 The event takes place online on the Confiva platform Confiva Global d.o.o.

Tickets

Loading ticket types...

Description

	Academic	Business
Viruses, VLPs and Nanoparticles (online)	300 €	400 €	Presentations will cover purification challenges of extracellular vesicles and lipid nanoparticles, along with efficient production of viruses and viral vectors for cell and gene therapy. Speakers will address characterization issues and provide solutions, guiding you through challenges from upstream processes to separating empty from full AAV capsids.
General Aspects of Purification Technologies (online)	175 €	250 €	Presentations will focus on purification strategies for advanced therapies, including enzymes, proteins, and other biomolecules. Speakers will explore the latest advancements and continuous improvement strategies in purification technology.
Nucleic acids (online)	300 €	400 €	Presentations will cover pDNA purification at various scales, focusing on purity and homogeneity for vaccines and gene therapy. Speakers will discuss efficient, scalable processes and the role of chromatography in mRNA production, including challenges and innovative solutions.
Viruses and General (online)	425 €	600 €	This package includes presentations for two distinct streams: Stream: Viruses, VLPs, and Nanoparticles Presentations will cover purification challenges of extracellular vesicles and lipid nanoparticles, along with efficient production of viruses and viral vectors for cell and gene therapy. Speakers will address characterization issues and provide solutions, guiding you through challenges from upstream processes to separating empty from full AAV capsids. Stream: General Aspects of Purification Technologies Presentations will focus on purification strategies for advanced therapies, including enzymes, proteins, and other biomolecules. Speakers will explore the latest advancements and continuous improvement strategies in purification technology.
Nucleic acids and General (online)	425 €	600 €	This package includes presentations for two distinct streams: Stream: Nucleic acids Presentations will cover pDNA purification at various scales, focusing on purity and homogeneity for vaccines and gene therapy. Speakers will discuss efficient, scalable processes and the role of chromatography in mRNA production, including challenges and innovative solutions. Stream: General Aspects of Purification Technologies Presentations will focus on purification strategies for advanced therapies, including enzymes, proteins, and other biomolecules. Speakers will explore the latest advancements and continuous improvement strategies in purification technology.
Viruses and Nucleic acids (online)	500 €	700 €	This package includes presentations for two distinct streams: Stream: Viruses, VLPs, and Nanoparticles Presentations will cover purification challenges of extracellular vesicles and lipid nanoparticles, along with efficient production of viruses and viral vectors for cell and gene therapy. Speakers will address characterization issues and provide solutions, guiding you through challenges from upstream processes to separating empty from full AAV capsids. Stream: Nucleic acids Presentations will cover pDNA purification at various scales, focusing on purity and homogeneity for vaccines and gene therapy. Speakers will discuss efficient, scalable processes and the role of chromatography in mRNA production, including challenges and innovative solutions.
Whole program (online)	600 €	800 €	This package includes presentations for all three streams: Stream:Viruses, VLPs, and Nanoparticles Presentations will cover purification challenges of extracellular vesicles and lipid nanoparticles, along with efficient production of viruses and viral vectors for cell and gene therapy. Speakers will address characterization issues and provide solutions, guiding you through challenges from upstream processes to separating empty from full AAV capsids. Stream: Nucleic acids Presentations will cover pDNA purification at various scales, focusing on purity and homogeneity for vaccines and gene therapy. Speakers will discuss efficient, scalable processes and the role of chromatography in mRNA production, including challenges and innovative solutions. Stream: General Aspects of Purification Technologies Presentations will focus on purification strategies for advanced therapies, including enzymes, proteins, and other biomolecules. Speakers will explore the latest advancements and continuous improvement strategies in purification technology.

Nucleic acids stream includes the following presentations:

Enabling CIMmultus DEAE columns at scale for plasmid DNA capture (Justina Martinkiene, AstraZeneca)

High-quality, phase-appropriate plasmid manufacturing to accelerate advanced therapies (John Bowen, Center for Breakthrough Medicines)

High-throughput manufacturing of personalized plasmid DNA cancer vaccines (Kathrin Seyrl, Biomay AG)

Sartorius In-Line Lysis System: Pioneering Success in Plasmid DNA Isolation (Matevž Korenč, Sartorius BIA Separations)

Debottlenecking vaccine manufacturing; effective supply of quality pDNA (Salomé De Sá Magalhães, Department of Biochemical Engineering)

Biotechnological platform to obtain a minicircle DNA vaccine targeting cervical cancer (Ângela Sousa, CICS-UBI)

Novel, synthetic DNA templates for the production of mRNA (Carmen Mañas Torres, 4basebio)

Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction (Diego Casabona Agudo,Certest Biotec)

End-to-end solutions for IVT mRNA therapeutic development (Daniel Meng, VectorBuilder)

Towards an efficient purification process for saRNA: exciting challenges and progress (Justine Jakpou, Ziphius Vaccines)

The many struggles and success of the establishing a pDNA manufacturing platform (Ahmet Hilmi Tekin, BioNTech Manufacturing Marburg)

An Integrated Perspective on mRNA Vaccine Process Development (Sara Sousa Rosa, University College London)

Development of immobilized enzyme reactors on monolith backbone for rapid plasmid DNA linearization (Maša Strašek, Sartorius BIA Separations)

Quality by design for mRNA platform purification based on continuous oligo-dT chromatography (Jixin Qu, University of Sheffield, Sheffield)

Chromatography in mRNA production: from analytics to purification (Rok Sekirnik, Sartorius BIA Separations)

Optimization of mRNA production and purification: characterization and controlling of post-transcriptional polyadenylation and its effect on mRNA quality in vitro (Pooja Tiwari, Arnav Biotech)

Innovating and digitalising mRNA vaccine and therapeutics production processes (Zoltán Kis, University of Sheffield)

Manufacturing of mRNA for preclinical and clinical studies (Tjaša Legen, BioNTech SE)

Engineering a robust and scalable mRNA manufacturing process (Bill Grier, Omega Therapeutics)

Next generation lipid nanoparticles for RNA vaccines and therapeutics (Dan Peer, NeoVac)

LipidBrick®: An innovative cationic lipid library for efficient and tunable mRNA-LNPs (Guillaume Freund, Polyplus)

Engineered EVs for mRNA cargo loading and delivery (Antje Zickler, Karolinska Institutet)

Thermodynamic analysis of chromatography media and mRNA properties in oligo dT affinity chromatography (Connor Smith, Orbital Therapeutics)

All-scale continuous mRNA-LNP manufacturing (Flora Binder, Dillico)

Monolithic columns enable streamlined downstream processing and analytics of lipid nanoparticles (Tristan Kovačič, Sartorius BIA Separations)

General Aspects of Purification Technologies stream includes the following presentations:

From first concepts to production and broad application of CIM monoliths for separation of macromolecules and nanoparticles and for continuous enzymatic conversion (Djuro Josić, University of Pula)

Tailoring surface of chromatographic monoliths to achieve higher separation performance for large biomolecules (Urh Černigoj, Sartorius BIA Separations)

Addressing materials and resolution challenges in the 3D printing of chromatography columns (Simone Dimartino, The University of Edinburgh)

Efficient and sustainable platform for preparation of a high-quality immunoglobulin G as an urgent treatment option during emerging virus outbreaks (Beata Halassy, University of Zagreb)

Selective capture and separation of blood plasma derived therapeutic proteins on a new monolithic media CIMmultus PrimaT (Yow-Pin Lim, ProThera Biologics)

Purification and glycosylation analysis of plasma proteins using 96-well monolithic plates (Irena Trbojević Akmacić, Genos)

Immobilized enzyme reactors as a cost-effective solution to enhance (bio)assay throughput (Manuela Bartolini, University of Bologna)

Novel monolithic capillary columns for multimodal (reversed-phase, hydrophilic interactions, chiral and achiral) capillary electrochromatography (Ziad El Rassi, Oklahoma State University)

Analytical toolbox for reliable characterization of extracellular vesicles (Aslan Mehdi Dehghani, Sartorius)

Poly(A) tail length determination with UV detection using ion pair reversed-phase liquid chromatography (Sergeja Lebar, Sartorius BIA Separations)

Selective hydrophobic interaction chromatography for high purity of supercoiled DNA plasmids (Ajda Sedlar, Sartorius BIA Separations)

HPLC for at-line reaction monitoring and purification improves yield and purity of tRNA (Polona Megušar, Sartorius BIA Separations)

Viruses, VLPs and Nanoparticles stream includes the following presentations:

Where does the cell and gene field need to go to thrive? Critical considerations as you move your programs forward (Andrew Knudten, Advanced Medicine Partners)

New approaches for viral vector genome integrity evaluation (David Dobnik, National Institute of Biology)

Development of capture and polishing chromatography steps using Sartorius CIM monolithic chromatography technology for a novel AAV serotype (Christopher Nieder, SK Pharmteco)

You don’t need affinity to purify rAAV Part 2 & beyond empty/full separation (Michael J. Hatfield, Advanced Medicine Partners)

Advancing AAV empty/full capsids separation with ExoReady™ platform: harnessing the power of monolithic columns (Tiago Albano, Exothera)

GET+VVIRAL: a purification toolbox for the gene-editing tools and viral vectors (Stefano Menegatti, North Carolina State University)

Two streams, a single process: optimizing AAV production for improved purification performance (Ivana Petrović Koshmak, Sartorius BIA Separations)

Limitations of various analytical techniques in characterizing recombinant adeno-associated virus empty capsids (Kazuhiro Oka, Baylor College of Medicine)

Clinical potential of MSC-EVs and translational challenges (Bernd Giebel, University Hospital Essen)

Leveraging New CIMmultus QA HR for Successful AAV Polishing - Optimization and Scale Up (Maja Leskovec, Sartorius BIA Separations)

Monoliths to bridge the gap between purity and yield in viral vectors downstream processing (Hana Jug, Sartorius BIA Separations)

Orthogonal chromatography analytics to allow for faster process development and better in-process control (Aleš Štrancar, Sartorius BIA Separations)

Gene therapy for retinal disorders - achievements and remaining challenges (Stylianos Michalakis, Ludwig Maximilian University of Munich)

Key points of Process Development and Characterization of AAV Gene Therapy Products (Ella Chan, Skyline Therapeutics)

High-throughput sequencing approaches for in-depth analysis of AAV-based gene therapies (Mojca Janc, National Institute of Biology)

Production and purification of Staphylococcus epidermidis phage Cop-80B for preclinical evaluation of its safety and efficacy for the treatment of orthopaedic-related chronic infections (Vida Štilec, COBIK)

Separation and functional characterization of stem cell-derived exosomes from scalable manufacturing processes (Klaus Graumann, Phoenestra)

Mechanistic modeling for the purification of a replicant-competent enveloped virus on a monolithic ion-exchange chromatography (Adrian Schimek, ViraTherapeutics)